

Claims

1. The use of an active ingredient for the prevention or treatment of tumors, in particular malignant tumors, where the active ingredient influences, in particular inhibits, the expression and/or the function of proteins synthesized and/or secreted by the tumor, in eukaryotic cells, and thus at least partially inhibits the increase in tissue volume and/or the metastasis of the tumor.
2. The use of an active ingredient for producing a medicament or a pharmaceutical composition for the prevention or treatment of tumors, where the active ingredient influences, in particular inhibits, the expression and/or the function of proteins synthesized and/or secreted by the tumor, in eukaryotic cells, and thus at least partially inhibits the increase in tissue volume and/or the metastasis of the tumor.
3. The use of a substance for detecting the expression and/or the function of proteins synthesized and/or secreted by tumors, in particular malignant tumors, in eukaryotic cells, for diagnosing disorders associated with these tumors.
4. A method for the prevention or treatment of tumors, in particular malignant tumors, characterized in that eukaryotic cells are treated with an active ingredient which influences, in particular inhibits, the expression and/or the function of proteins synthesized and/or secreted by tumors, and thus at least partially inhibits the increase in tissue volume and/or the metastasis of the tumors.
5. A method for diagnosing disorders associated with tumors, in particular malignant tumors, characterized in that eukaryotic cells are brought into contact with a substance which detects the expres-

sion and/or the function of proteins synthesized and/or secreted by tumors.

- 5 6. The use or method as claimed in any of claims 1 to 5, characterized in that the proteins synthesized and/or secreted by tumors are the proteins of table I, in particular the isoforms thereof.
- 10 7. The use or method as claimed in any of the preceding claims, characterized in that the active ingredient or the substance is directed against the proteins synthesized and/or secreted by tumors.
- 15 8. The use or method as claimed in any of the preceding claims, characterized in that the active ingredient or the substance is directed against activators, inhibitors, regulators and/or biological precursors of proteins synthesized and/or secreted by tumors.
- 20 9. The use or method as claimed in any of the preceding claims, characterized in that the active ingredient or the substance is a polynucleotide which encodes a peptide, in particular a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and/or function of proteins synthesized and/or secreted by tumors.
- 25 10. The use or method as claimed in any of claims 1 to 8, characterized in that the active ingredient or the substance is a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and/or function of proteins synthesized and/or secreted by tumors.
- 30 11. The use or method as claimed in any of the preceding claims, characterized in that the active ingredient or the substance is a small molecular compound, preferably a small molecular com-

pound having a molecular weight (MW) of < 1000.

12. The use or method as claimed in any of the preceding claims,
characterized in that the malignant tumors are prostatic carcinomas.
13. The use or method as claimed in any of the preceding claims,
characterized in that the active ingredient or the substance can be
administered orally, intravenously, topically and/or by inhalation.
14. A pharmaceutical composition comprising an effective amount of
at least one active ingredient which influences, in particular inhibits,
the expression and/or function of proteins synthesized and/or
secreted by tumors, in particular malignant tumors, and where appropriate
a pharmaceutical carrier.
15. The pharmaceutical composition as claimed in claim 14, characterized
in that the active ingredient is a polynucleotide which encodes a peptide,
in particular a polypeptide, this peptide preferably influencing, in particular
inhibiting, the expression and/or function of proteins synthesized and/or
secreted by tumors, in particular malignant tumors.
16. The pharmaceutical composition as claimed in claim 14, characterized
in that the active ingredient is a peptide, preferably a polypeptide, this
peptide preferably influencing, in particular inhibiting, the expression and/or
function of proteins synthesized and/or secreted by tumors, in particular
malignant tumors.
17. The pharmaceutical composition as claimed in any of claims 14 to
16, characterized in that the active ingredient is a small molecular
compound, preferably a small molecular compound having a mo-

molecular weight (MW) of < 1000.

18. A pharmaceutical composition comprising an effective amount of at least one active ingredient which influences, in particular inhibits, the expression and/or function of activators, inhibitors, regulators and/or biological precursors of proteins synthesized and/or secreted by tumors, in particular malignant tumors, and where appropriate a pharmaceutical carrier.
19. The pharmaceutical composition as claimed in claim 18, characterized in that the active ingredient is a polynucleotide which encodes a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and/or function of activators, inhibitors, regulators and/or biological precursors of proteins synthesized and/or secreted by tumors, in particular malignant tumors.
20. The pharmaceutical composition as claimed in claim 18, characterized in that the active ingredient is a peptide, preferably a polypeptide, this peptide preferably influencing, in particular inhibiting, the expression and/or function of activators, inhibitors, regulators and/or biological precursors of proteins synthesized and/or secreted by tumors, in particular malignant tumors.
21. The pharmaceutical composition as claimed in any of claims 18 to 20, characterized in that the active ingredient is a small molecular compound, preferably a small molecular compound having a molecular weight (MW) of < 1000.
22. A diagnostic kit comprising at least one substance for detecting the expression and/or function of proteins synthesized and/or secreted by tumors, in particular malignant tumors, for diagnosing

disorders associated with these tumors.

23. The diagnostic kit as claimed in claim 22 for diagnosing prostatic carcinomas.
